Effect of metalloprotease inhibitors on corneal allograft survival

Investigative Ophthalmology and Visual Science

Volumn 45, Issue 4, 2004, Pages 1169-1173

  Stuart, Patrick M ^a,c   Pan, Fan ^a   Yin, Xiaotang ^a   Haskova, Zdenka ^a,b   Plambeck, Stacey ^a   Ferguson, Thomas A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACITRACIN; BATIMASTAT; DOXYCYCLINE; FAS LIGAND; KB 8301; KN 8301; MEMBRANE PROTEIN; METALLOPROTEINASE INHIBITOR; NEOMYCIN; POLYMYXIN B; UNCLASSIFIED DRUG; DIPEPTIDE; DRUG DERIVATIVE; FASL PROTEIN, MOUSE; FASLG PROTEIN, HUMAN; HSCH2CH(CH2CH(CH3)2)CO PHE ALA NH2; HSCH2CH(CH2CH(CH3)2)CO-PHE-ALA-NH2; MATRIX METALLOPROTEINASE; PHENYLALANINE; PROTEINASE INHIBITOR; THIOPHENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL KILLING; CONTROLLED STUDY; CORNEA ENDOTHELIUM; CORNEA TRANSPLANTATION; DRUG EFFECT; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMAN CELL; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TARGET CELL; ALLOTRANSPLANTATION; ANIMAL; C57BL MOUSE; CELL CULTURE; DRUG ANTAGONISM; FLOW CYTOMETRY; METABOLISM; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; SKIN TRANSPLANTATION;

ANIMALS; CELLS, CULTURED; CORNEAL TRANSPLANTATION; DIPEPTIDES; DOXYCYCLINE; ENDOTHELIUM, CORNEAL; FAS LIGAND PROTEIN; FEMALE; FLOW CYTOMETRY; GRAFT SURVIVAL; HUMANS; MALE; MATRIX METALLOPROTEINASES; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, INBRED MRL LPR; PHENYLALANINE; PROTEASE INHIBITORS; SKIN TRANSPLANTATION; THIOPHENES; TRANSPLANTATION, HOMOLOGOUS;

EID: 2142643101     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.03-0932     Document Type: Article

References (42)

1. Edwards M, Clover GM, Brookes N, Pendergrast D, Chaulk J, McGhee CN. Indications for corneal transplantation in New Zealand: 1991-1999. Cornea. 2002;21:152-155.
2. Thompson RW, Price MO, Bowers PJ, Price FW. Long-term survival after penetrating keratoplasty. Ophthalmology. 2003;110:1396-1402.
3. Williams KA, Roder D, Esterman A, Muehlberg SM, Coster DJ. Factors predictive of corneal graft survival: report form the Australian Corneal Graft Registry. Ophthalmology. 1992;99:403-414.
4. Larkin DF. Corneal allograft rejection. Br J Ophthalmol. 1994;78:649-652.
5. Boisjoly HM, Taourigny R, Bazin R, et al. Risk factors of corneal graft failure. Ophthalmology. 1993;100:1728-1735.
6. Ferguson TA, Griffith TS. A vision of cell death: insights into immune privilege. Immunol Rev. 1997;156:167-184.
7. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270:1189-1192.
8. Griffith TS, Yu X, Herndon JM, Green DR, Ferguson TA. CD-95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity. 1996;5:7-16.
9. Goldberg M F, Ferguson TA, Pepose JS. Detection of cellular adhesion molecules in inflamed human corneas. Ophthalmology. 1994;101:161-168.
10. Sonoda KH, Taniguchi M, Stein-Streilein J. Long-term survival of corneal allografts is dependent on intact CD1d-reactive NKT cells. J Immunol. 2002;168:2028-2034.
11. Kaplan HJ, Leibole MA, Tezel T, Ferguson TA. Fas ligand (CD95 ligand) controls angiogenesis beneath the retina. Nat Med. 1999;5:292-297.
12. Stuart PM Pan F, Plambeck S, Ferguson TA. Fas/Fas ligand interactions regulate neovascularization in the cornea. Invest Ophthalmol Vis Sci. 2003;44:93-98.
13. Maguire MG, Stark WJ, Gottsch JD, et al. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Ophthalmology. 1994;101:1536-1547.
14. Sano Y, Ksander BR, Streilein JW. Fate of orthotopic corneal allografts in eyes that cannot support anterior chamber-associated immune deviation induction. Invest Ophth Vis Sci. 1995;36:2176-2185.
15. Cohen RA, Gebhardt BM, Bazan NG. A platelet-activating factor antagonist reduces corneal allograft inflammation and neovascularization. Curr Eye Res. 1994;13:139-144.
16. Olsen TW, Benegas NM, Joplin AC, Evangelista T, Mindrup EA, Holland EJ. Rapamycin inhibits corneal allograft rejection and neovascularization. Arch Ophthalmol. 1994;112:1471-1475.
17. Pepper MS, Montesano R. Proteolytic balance and capillary morphogenesis. Cell Diff Dev. 1990;332:319-328.
18. Martrisian LM. The matrix degrading metalloproteinases. Bioassays. 1992;14:455-463.
19. Lee S, Zheng M, Kim B, Rouse BT. Role of matrix metalloproteinase-9 in angiogenesis caused by ocular infection with herpes simplex virus. J Clin Invest. 2002;110:1105-1111.
20. Lin MT, Chen YT. Effect of copper ion on collagenase release: its implication in corneal neovascularization. Invest Ophthalmol Vis Sci. 1992;33:558-563.
21. Postlethwaite AE, Lachmann L, Mainardi LC, Kang AH. Interleukin 1 stimulation of collagenase production by cultured fibroblasts. J Exp Med. 1983;157:801-806.
22. MacNaul KL, Chartrain N, Lark M, Tocci MJ, Hutchinson NI. Discoordinate expression of stromelysin, collagenase and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts: synergistic effects of interleukin-1 and tumor necrosis factor-α on stromelysin expression. J Biol Chem. 1990;265:17238-17245.
23. Xue ML, Wakefield D, Willcox MDP, et al. Regulation of MMPs and TIMPs by IL-1β during corneal ulceration and infection. Invest Ophthalmol Vis Sci. 2003;44:2020-2025.
24. Kayagaki N, Kawasaki A, Ebata T, et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med. 1995;182:1777-1783.
25. Stuart PM, Griffith TS, Usui N, Pepose JS, Yu X, Ferguson TA. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest. 1997;99:396-402.
26. Fini ME, Girard MT. Expression of collagenolytic/gelatinolytic metalloproteinases by normal cornea. Invest Ophthalmol Vis Sci. 1990;31:1779-1788.
27. Sonoda Y, Streilein JW. Orthotopic corneal transplantation in mice: evidence that the immunogenetic rules of rejection do not apply. Transplantation. 1992;54:694-704.
28. Joo C-K, Pepose JS, Stuart PM. T-cell mediated responses in a murine model of orthotopic corneal transplantation. Invest Ophthalmol Vis Sci. 1995;36:1530-1540.
29. Stuart PM, Melvold RW, Beck-Maier B. Provocation of skin graft rejection across murine class II differences by non-bone-marrow-derived cells. Transplantation. 1984;37:393-396.
30. Joo C-K, Pepose JS Fleming TP. In vitro propagation of primary and extended life span murine corneal endothelial cells. Invest Ophthalmol Vis Sci. 1994;35:3952-3957.
31. Stuart PM, Woodward JG. Yersinia enterocolitica produces super-antigenic activity. J Immunol. 1992;148:225-233.
32. Yamagami S, Kawashima H, Tsuru T, et al. Role of Fas-Fas ligand interactions in the immunorejection of allogeneic mouse corneal transplants. Transplantation. 1997;64:1107-1111.
33. Allison J, Georgiou HM, Strasser A, Vaux DL. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci USA. 1997;94:5986-5990.
34. Kang SM, Schneider DB, Lin Z, et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med. 1997;3:738-743.
35. Bourne WM. Cellular changes in transplanted human corneas. Cornea. 2001;20:560-569.
36. Plskova J, Kuffova L, Holan V, Filipec M, Forrester JV. Replacing the endothelium without corneal surface incisions or sutures: the first United States clinical series using the deep lamellar endothelial keratoplasty procedure. Br J Ophthalmol. 2002;86:108-113.
37. Haskova Z, Filipec M, Holan V. The role of major and minor histocompatibility antigens in orthotopic corneal transplantation in mice. Folia Biol (Praha). 1996;42:105-111.
38. + T cells are critical for corneal, but not skin, allograft rejection. Transplantation. 2000;69:483-487.
39. Ahonen M, Poukkula M, Baker AH, et al. Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors. Oncogene. 2003;22:2121-2134.
40. Solomon A, Rosenblatt M, Li D-Q, et al. Doxycycline inhibition of Interleukin-1 in the corneal epithelium. Invest Ophthalmol Vis Sci. 2000;41:2544-2557.
41. Schoenbeck U, Mach F, Libby P. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1 independent pathway of IL-1 beta processing. J Immunol. 1998;161:3340-3346.
42. Yamada J, Zhu SN, Streilein JW, Dana MR. Interleukin-1 receptor antagonist therapy and induction of anterior chamber-associated immune deviation-type tolerance after corneal transplantation. Invest Ophthalmol Vis Sci. 2000;41:4203-4208.